Corporate Banner
Satellite Banner
Biologics & Bioprocessing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Novasep Discovers Explosive Properties of Togni Reagent II

Published: Wednesday, April 17, 2013
Last Updated: Wednesday, April 17, 2013
Bookmark and Share
Novasep reclassifies reagent and informs market about new safety measures required.

Novasep has announced that its R&D team has discovered and characterized the explosive properties of the Togni reagent II and intermediates at the Novasep Leverkusen site in Germany.

The findings have been published in the March edition of the journal Organic Process Research and Development.

Togni reagent II (1-(trifluoromethyl)-1,2-benziodoxol-3(1H)-one, 1) is a versatile reagent for the electrophilic introduction of trifluoromethyl groups. It is used in pharmaceutical manufacturing. It is also widely used in universities.

Novasep conducted a Koenen test on a sample of Togni Reagent II prepared in their kilolab, in which the reagent was shown to be highly explosive.

Another critical property of the Togni Reagent II clarified by the Novasep team is its fast combustion when ignited. The combustion factor was measured as BZ6, the same classification as black powder.

This discovery has resulted in a revised classification for handling and transportation of the Togni reagent II, which must now be approved by national competent authorities.

Novasep has also informed companies known to market the compound, who will relay the safety measures required to handle the reagent.

Tests were conducted in the Novasep Leverkusen plant. The plant has German government authorization to handle energetic materials and operate hazardous reactions from lab to thousands tons scale.

This has enabled Novasep to develop reliable and cost-efficient processes that satisfy regulatory requirements whilst maintaining safety for technical staff and its plants.

The skill developed by Novasep includes managing large-scale reactions that use sodium azide, reactive metals, diazomethane and diborane (both in gaseous form), hydrazine, ozone and nitroalkanes.

These chemical reactions are often more direct and cost-efficient than traditional routes of synthesis. They generally create fewer by-products and have a high yield and productivity.

“Novasep has used our 140 years experience and the knowledge of our R&D team in highly energetic reagents and reactions as well as our specialized equipment to be able to identify another set of dangerous properties of a commonly used compound,” said Dr. Jan Haller, senior scientist, process development, Novasep.

Dr. Haller continued, “We consider it very important to share this knowledge with scientific, manufacturing and regulatory communities to ensure that this compound is treated in a safe manner.”

“The work completed by Novasep regarding the Togni Reagent II will contribute to a more deliberate and responsible handling of the reagent used by so many research groups," said Professor Togni, professor of organometallic chemistry at the Laboratory of Inorganic Chemistry, ETH Zurich and inventor of the reagent.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Novasep Further Strengthens Management Team
Pierre-Louis Mikus joins as chief legal officer and Bertrand Waymel is promoted to group human resources director.
Wednesday, May 06, 2015
Novasep and Celladon Execute MYDICAR API Supply Agreement
An innovative, genetically-targeted enzyme replacement therapy based on AAV1/SERCA2a.
Thursday, March 26, 2015
Novasep Enters into an Agreement with Celladon
Company selected to commercially biomanufacture Celladon's Mydicar API.
Thursday, February 19, 2015
Novasep’s €4 M ADC Manufacturing Plant Extension Commissioned
The new Highly Potent API manufacturing capacity at the Le Mans facility will boost Novasep’s ability to meet customer demand for producing anti-cancer therapies.
Friday, May 16, 2014
Novasep Appoints CEO Michel Spagnol as Chairman
Novasep presents strategic developments.
Wednesday, March 05, 2014
Novasep Opens Indian Subsidiary
New office will meet India’s increasing need for high efficacy processes for its fast growing food and feed industries.
Tuesday, December 10, 2013
Novasep’s European Custom Manufacturing Passes FDA Inspection
Two successful FDA inspections assure customers of Novasep’s strict compliance with US pharmaceutical processing standards.
Thursday, October 24, 2013
Novasep Appoints Christian Thiry as Chief Financial Officer
CFO appointment is a key milestone in Novasep’s senior management recruitment program.
Thursday, August 29, 2013
Novasep Appoints President and CEO
Novasep announces the appointment of Michel Spagnol as President and CEO of the company, effective from 25 June 2013.
Thursday, June 27, 2013
Novasep Appoints Fine Chemicals Market Director
Company strengthens its position by appointing Udo Steinhauer.
Thursday, June 06, 2013
Novasep Invests to Build World's Largest Chromatography Plant for the Pharmaceutical Industry
The investment of €30 million allows Novasep to build the largest chromatography plant for the production of a large volume commercial API’s in Mourenx, France.
Wednesday, October 10, 2012
Changes to Novasep Governance
Roger-Marc Nicoud becomes non-executive chairman of the board.
Wednesday, October 03, 2012
Novasep Announces Three Million Euro Investment
Company to boost its highly potent API manufacturing capabilities in Le Mans, France.
Friday, July 20, 2012
Novasep Strengthens its Management Team with Key Appointments
Appointment of Jean-Claude Romain as corporate quality director and Alain Lamproye as director of Novasep Bioproduction sites in Belgium.
Tuesday, April 24, 2012
Novasep Opens New Shanghai Facilities
New site increases Novasep’s process development and engineering capabilities to supply turnkey purification processes in East Asia.
Thursday, March 29, 2012
Scientific News
Less May Be More in Slowing Cholera Epidemics
Mathematical model shows more cases may be prevented and more lives saved when using one dose of cholera vaccine instead of recommended two doses.
NIH Launches Human RSV Study
Study aims to understand infection in healthy adults to aid development of RSV medicines, vaccines.
Flu Remedies Help Combat E. coli Bacteria
Physiologists from the University of Zurich have now discovered why the intestinal bacterium Escherichia coli (E. coli) multiplies heavily and has an inflammatory effect.
'Fountain of Youth' Protein Points to Possible Human Health Benefit
Patients with higher blood levels of growth factor have lower risk of cardiovascular problems.
Lemon Juice and Human Norovirus
Citric acid may prevent the highly contagious norovirus from infecting humans, scientists discovered from the German Cancer Research Center.
Study Backs Flu Vaccinations for Elderly
Brown University researchers found vaccines well matched to the year’s flu strain significantly reduce deaths and hospitalizations compared to when the match is poor, suggesting that vaccination indeed makes a difference.
Inciting an Immune Attack on Cancer Cells
A new minimally invasive vaccine that combines cancer cells and immune-enhancing factors could be used clinically to launch a destructive attack on tumors.
Protein Found to Play a Key Role in Blocking Pathogen Survival
Calprotectin fends off microbial invaders by limiting access to iron, an important nutrient.
Major Advance Toward More Effective, Long-Lasting Flu Vaccine
Collaboration shows vaccine candidate can produce powerful ‘broadly neutralizing antibodies’ in animal models.
Immune System: Help for Killer Cells
A study from the University of Bonn may show the way to more effective vaccines.
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!